An Open-Label, Phase 2 Study to Evaluate the Activity of Belumosudil in Subjects With New Onset and Incipient Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell Transplantation

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Aug 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Azithromycin (Primary) ; Belumosudil (Primary) ; Fluticasone propionate (Primary) ; Montelukast (Primary) ; Prednisone (Primary)
Indications Bronchiolitis obliterans
Focus Therapeutic Use
Acronyms BEBOP

12 Jun 2024 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
12 Jun 2024 Planned primary completion date changed from 31 Dec 2024 to 30 Jun 2026.
16 Jan 2024 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com